共 50 条
- [1] Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC)LUNG CANCER, 2005, 49 : S53 - S54Langer, CHanna, NEinhorn, LSandler, AAnsari, REllis, RByrne, MGreen, MMorrison, MBunn, P
- [2] S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Natale, R. B.Lara, P. N.Chansky, K.Crowley, J. J.Jett, J. R.Carleton, J. E.Kuebler, J. P.Lenz, H. J.Mack, P. C.Gandara, D. G.
- [3] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancerJOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2038 - 2043Hanna, NBunn, PALanger, CEinhorn, LGuthrie, TBeck, TAnsar, REllis, PByrne, MMorrison, MHariharan, SWang, BSandler, A
- [4] Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancerCLINICAL LUNG CANCER, 2006, 7 (05) : 353 - 356Lara, Primo N., Jr.Gandara, David R.Natale, Ronald B.
- [5] PHASE III TRIAL COMPARING IRINOTECAN PLUS CISPLATIN (IP) WITH ETOPOSIDE PLUS CISPLATIN (EP) IN KOREAN PATIENTS WITH EXTENSIVE DISEASE (ED) SMALL CELL LUNG CANCER (SCLC)JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S219 - S220Kim, Dong-WanKim, Hoon-GuKim, Joo-HangPark, KeunchilKim, Hoon KyoJang, Joung SoonKim, Bong-SeogKang, Jin-HyoungLee, Kyung HeeKim, Sang-WeRyoo, Hun MoKim, Jin-SooLee, Ki HyeongKwon, Jung HyeChoi, Jin-HyukHong, Dae SikShin, Sang WonHahn, SeokyungHeo, Dae Seog
- [6] Cisplatin Combined with Irinotecan or Etoposide for Untreated Extensive-Stage Small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S625 - S625Shi, YuankaiHu, XingshengHu, YiHan, XiaohongLi, XueLin, Lin
- [7] Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trialBMC CANCER, 2016, 16Oh, In-JaeKim, Kyu-SikPark, Cheol-KyuKim, Young-ChulLee, Kwan-HoJeong, Jin-HongKim, Sun-YoungLee, Jeong-EunShin, Kye-ChulJang, Tae-WonLee, Hyun-KyungLee, Kye-YoungLee, Sung-Yong
- [8] Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trialBMC Cancer, 16In-Jae OhKyu-Sik KimCheol-Kyu ParkYoung-Chul KimKwan-Ho LeeJin-Hong JeongSun-Young KimJeong-Eun LeeKye-Chul ShinTae-Won JangHyun-Kyung LeeKye-Young LeeSung-Yong Lee
- [9] Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysisJOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S1076 - S1083Liu, Zi-LiWang, BinLiu, Ji-ZhuLiu, Wei-Wei
- [10] Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)ANNALS OF ONCOLOGY, 2021, 32 : S1165 - S1165Takahashi, T.Mori, K.Mizuno, R.Mamesaya, N.Kobayashi, H.Omori, S.Wakuda, K.Ono, A.Naito, T.Murakami, H.Kenmotsu, H.